Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
Journal of Allergy and Clinical Immunology · 2024-07 · 154 (1) · 184-194
DOI: 10.1016/j.jaci.2024.01.028 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Allergy and Clinical Immunology, 2024-07. Verfasst von Marcus Maurer und 18 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität, Berlin, and Humboldt-Universität zu Berlin, Berl…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Chronic Urticaria. Die Arbeit wurde bisher 173-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi US.
Abstract (Originalsprache)
BACKGROUND: Chronic spontaneous urticaria (CSU) is a chronic inflammatory disease characterized by recurrent pruritic wheals (hives) and/or angioedema. Patients with CSU could remain symptomatic despite standard-of-care H1 antihistamines (H1-AH) or anti-IgE (omalizumab) treatment. Dupilumab blocks IL-4/IL-13 signaling and is approved for multiple type 2/atopic indications. OBJECTIVE: We conducted two phase 3, randomized, placebo-controlled, double-blind trials comparing dupilumab with placebo in patients with symptomatic CSU despite H1-AH. METHODS: In LIBERTY-CSU CUPID Study A, patients were omalizumab-naive (n = 138, aged ≥6 years). In Study B, patients were omalizumab-intolerant/incomplete responders (n = 108, aged ≥12 years). The primary end point was either change from baseline over 7 days in the Urticaria Activity Score (UAS7) or Itch Severity Score (ISS7) at week 24, with the other as a key secondary end point, depending on regional regulatory requirements. Studies were pooled for safety assessment. RESULTS: In Study A, UAS7 and ISS7 improved with dupilumab versus placebo (difference -8.5 [95% CI, -13.2 to -3.9; P = .0003] and -4.2 [95% CI, -6.6 to -1.8; P = .0005]). In Study B, tested at α = 0.043 after interim analysis, UAS7 improved (difference -5.8 [95% CI, -11.4 to -0.3; P = .0390]), with a numerical trend in ISS7 (difference -2.9 [95% CI, -5.7 to -0.07; nominal P = .0449, not significant]). Pooled safety data were consistent between dupilumab and placebo and with the known dupilumab safety profile. CONCLUSIONS: Dupilumab reduced urticaria activity by reducing itch and hives severity in omalizumab-naive patients with CSU uncontrolled with H1-AH. Although the primary end point for Study B was not met, dupilumab effects were small in patients who were omalizumab-intolerant/incomplete responders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität, Berlin, and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharm…
- Division of Allergy and Immunology, Department of Medicine, University of South Florida, Tampa, Fla.
- Johns Hopkins Asthma and Allergy Center, Baltimore, Md.
- Division of Allergy, Immunology, and Dermatology, Department of Pediatrics, McGill University Health Centre, Montreal, Quebec, Canada.
- Department of Dermatology, Hospital del Mar, Institut Mar D'Investigacions Mediques, Universitat Autónoma y Universitat Pompeu Fabra, Barcelona, Spain.
- Division of Allergy and Immunology, Department of Internal Medicine, University of Cincinnati College of Medicine, Partner Bernstein Allergy Group and Bernstein Clinical Research Center, Cincinnati, Ohio.
Förderung
- Sanofi US
Zitieren
APA
Maurer, M., Casale, T. B., Saini, S. S., Ben-Shoshan, M., Giménez-Arnau, A. M., Bernstein, J. A., Yagami, A., Stjepanovic, A., Radin, A., Staudinger, H. W., Patel, N., Amin, N., Akinlade, B., Fan, C., Bauer, D., Yancopoulos, G. D., Patel, K., Mannent, L. P., & Laws, E. (2024). Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials. Journal of Allergy and Clinical Immunology, 154(1), 184-194. https://doi.org/10.1016/j.jaci.2024.01.028
Vancouver
Maurer M, Casale TB, Saini SS, Ben-Shoshan M, Giménez-Arnau AM, Bernstein JA, et al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials. Journal of Allergy and Clinical Immunology. 2024;154(1):184-194. doi:10.1016/j.jaci.2024.01.028
BibTeX
@article{Maurer2024,
author = {Maurer, Marcus and Casale, Thomas B and Saini, Sarbjit S and Ben-Shoshan, Moshe and Giménez-Arnau, Ana M and Bernstein, Jonathan A and Yagami, Akiko and Stjepanovic, Aleksandra and Radin, Allen and Staudinger, Heribert W and Patel, Naimish and Amin, Nikhil and Akinlade, Bolanle and Fan, Chunpeng and Bauer, Deborah and Yancopoulos, George D and Patel, Kiran and Mannent, Leda P and Laws, Elizabeth},
title = {Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials},
journal = {Journal of Allergy and Clinical Immunology},
year = {2024},
volume = {154},
number = {1},
pages = {184--194},
doi = {10.1016/j.jaci.2024.01.028}
}
EUVIMED